Diasorin S.p.a. · MIL:DIA
Diasorin — Investor Day (2026)
7 slides from Diasorin's investor day presentation, Sep 30, 2026
Slide 1: 05 Licensed Technologies
05 LICENSED TECHNOLOGIES Angelo Rago
Slide 2: Licensed Technologies: Enabling Innovation & Value Creation
05 | LICENSED TECHNOLOGIES Market Environment Licensed Technologies: Enabling Innovation & Value Creation 2025 LTG Revenue & Segments Life Science Research • Basic Research • Applied Research Royalties on kit sales 38% 7% % Pharma • Drug Discovery FY’25 • Vaccines Development $ Diagnostics $$$ & Res
Slide 3: Diagnostics
05 | LICENSED TECHNOLOGIES Market Environment | Diagnostics Diagnostics Products Diagnostic Kits Diasorin serves diagnostic partners that create specialty applications Multi- Transplant Autoimmune pathogen Transplant diagnostics Autoimmune & ID Diagnostics Testing services (biomarker LDTs) IVD Instr
Slide 4: Life Science Research
05 | LICENSED TECHNOLOGIES Market Environment | Life Science Research Life Science Research Products Research Use Only Kits Diasorin serves Life Science partners who provide Quantitative Gene Biomarker ready-to-use multi-analyte panels to power pharma Proteomics Expression Panels discovery and acade
Slide 5: Pharma
05 | LICENSED TECHNOLOGIES Market Environment | Pharma Pharma Products RUO Kits & Ingredients for GLP Assays Diasorin enables pharmaceutical companies to develop Drug Discovery Multivalent Vaccines specialty and proprietary assays for drug and vaccine development Assay Kits Microspheres Assay Suppor
Slide 6: Key Takeaways on Licensed Technologies
05 | LICENSED TECHNOLOGIES Key Takeaways Key Takeaways on Licensed Technologies Revenue base Diversified business model Highly recurring and high-quality Diagnostics, Life Science Research and Pharma Exposure to multiple end- markets • Diagnostics: stable and profitable core (growth in line with the
Slide 7: Slide 7